AstraZeneca vs Merck & Co
AstraZeneca (AZN), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Merck & Co is worth $354.4B on the stock market and AstraZeneca $283.9B: Merck & Co is valued at 25% more. AstraZeneca trades at 25.9 times earnings and Merck & Co at 145. Over the past year AstraZeneca's share price has moved +2.75% and Merck & Co's +49.8%.
Key facts
- AstraZeneca market value
- $283.9B
- Merck & Co market value
- $354.4B
- AstraZeneca P/E
- 25.9
- Merck & Co P/E
- 145
- AstraZeneca revenue
- $58.7BFY to 2025-12-31
- Merck & Co revenue
- $65BFY to 2025-12-31
- Superinvestors holding both
- 6
Market values as of .
| Measure | AstraZeneca | Merck & Co |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $283.9Blower | $354.4Bhigher |
| Revenue | $58.7Blower | $65Bhigher |
| Earnings | $10.2Blower | $18.3Bhigher |
| Employees | 96,100higher | 73,000lower |
| Total assets | $114.1Blower | $136.9Bhigher |
| Valuation | ||
| P/E | 25.9lower | 145higher |
| P/S | 4.8lower | 5.5higher |
| P/B | — | 7.9 |
| Dividend yield | — | 2.33% |
| Profitability | ||
| Operating margin | 23.4% | — |
| Balance sheet | ||
| Net assets | $48.7Blower | $52.6Bhigher |
| Total liabilities | $65.4Blower | $84.2Bhigher |
| Total debt | $29.6Blower | $49.3Bhigher |
| Cash on hand | $5.7Blower | $14.6Bhigher |
| Price change | ||
| Today | -0.52%lower | -0.48%higher |
| 1 year | +2.75%lower | +49.8%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (6)
- Sarah Ketterer20.2% / 0.6%
- Brandon Haley1.1% / 0.2%
- Ken Fisher0.5% / 1.7%
- Temasek0.4% / 0.3%
- Dodge & Cox team<0.1% / <0.1%
- Rajiv Jain<0.1% / <0.1%
AstraZeneca only (6)
- Primecap team1.8%
- Lew Sanders1.1%
- Larry Robbins0.7%
- Andrew Spokes0.4%
- Steve Cohen0.2%
- Polen Capital team<0.1%
Merck & Co only (17)
- Bill Smead7.1%
- Thomas Kahn4.9%
- Bill Nygren2.1%
- Howard Gleicher2.0%
- Jeremy Grantham (co-founder)1.6%
- Charles Brandes (founder)1.5%
- Josef Lakonishok1.4%
- Prem Watsa0.9%
- Christopher Bloomstran0.6%
- Mark Boyar0.5%
- Cliff Asness0.4%
- David Shaw (founder)0.2%
- Joel Greenblatt0.2%
- Ken Griffin0.1%
- Mairs & Power team0.1%
- Murray Stahl0.1%
- Thomas Russo<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Merck & Co). Who owns AZN · Who owns MRK
More on AstraZeneca
Further comparisons
AstraZeneca against its closest peers
Merck & Co against its closest peers
Learn
Questions and answers
Which is bigger, AstraZeneca or Merck & Co?
By market value, Merck & Co is the larger: $354.4B against $283.9B for AstraZeneca. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $58.7B for AstraZeneca.
Which has the higher P/E ratio?
Merck & Co: 145, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Merck & Co: $49.3B, against $29.6B for AstraZeneca. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both AstraZeneca and Merck & Co?
In their latest 13F filings, Sarah Ketterer, Brandon Haley, Ken Fisher, Temasek, Dodge & Cox team and Rajiv Jain hold both.
Cite this page
Funkfolio, “AstraZeneca vs Merck & Co”, data as of 17 November 2026. https://funkfolio.com/compare/azn-vs-mrk
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.